TG Therapeutics Inc(TGTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:47 PM ET (Korea 10/28 05:47)
Full metrics table
| Index | RUT | P/E | 20.56 | EPS (ttm) | 2.75 | Insider Own | 7.47% | Shs Outstand | 153.1M | Perf Week | 3.5% |
| Market Cap | 8.64B | Forward P/E | 19.64 | EPS next Y | 187.56% | Insider Trans | -0.04% | Shs Float | 141.6M | Perf Month | 0.44% |
| Enterprise Value | 8.84B | PEG | 1.94 | EPS next Q | 0.37 | Inst Own | 72.88% | Short Float | 20.89% | Perf Quarter | 5.53% |
| Income | 0.44B | P/S | 10.81 | EPS this Y | -63.91% | Inst Trans | 4.09% | Short Ratio | 15.42 | Perf Half Y | 63.22% |
| Sales | 0.80B | P/B | 14.3 | EPS next 5Y | 10.12% | ROA | 37.7% | Short Interest | 29.59M | Perf YTD | 89.33% |
| Book/sh | 3.95 | P/C | 15.64 | EPS past 3/5Y | - | ROE | 100.28% | 52W High | -4.82% ($59.30) | Perf Year | 67.53% |
| Cash/sh | 3.61 | P/FCF | 496.79 | Sales past 3/5Y | 504.86% 426.73% | ROIC | 32.54% | 52W Low | 110.91% ($26.76) | Perf 3Y | 710.92% |
| Dividend Est. | - | EV/EBITDA | 64.3 | EPS Y/Y TTM | 634.54% | Gross Margin | 82.37% | Volatility(W/M) | 4.67% 4.01% | Perf 5Y | 81.71% |
| Dividend TTM | - | EV/Sales | 11.06 | Sales Y/Y TTM | 76.08% | Oper. Margin | 17.05% | ATR (14) | 2.27 | Perf 10Y | 884.99% |
| Dividend Ex-Date | - | Quick Ratio | 3.72 | EPS Q/Q | -71.45% | Profit Margin | 55.22% | RSI (14) | 57.25 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.27 | Sales Q/Q | 70.27% | SMA20 | 4.04% ($54.25) | Beta | 1.91 | Target Price | $69.71 |
| Payout | - | Debt/Eq | 1.25 | Earnings | 2026/8/3 | SMA50 | 2.9% ($54.85) | Rel Volume | 0.77 | Prev Close | $54.79 |
| Employees | 399 | LT Debt/Eq | 1.25 | EPS/Sales Surpr. | -83.64% 4.6% | SMA200 | 30.2% ($43.35) | Avg Volume(3M) | 1.92M | Price | $56.44 |
| IPO | 1995/12/14 | Option/Short | Yes/Yes | Trades | 12821 | Volume | 1,484,887 | Change | 3.01% |
🧬 This is a commercial-stage biotech company that develops and sells treatment for multiple sclerosis. It generates rapidly growing revenue by selling an antibody therapy for relapsing forms of multiple sclerosis, and is a healthcare stock advancing a pipeline of additional formulations and indications such as a subcutaneous injectable version. Its core treatment's revenue and the competitive landscape drive its value.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
TGTX makes money exceptionally well
Of every $100 in sales, $17.05 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -63.9% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $2,056. Peers typically go for $1,456. Compared with its own 3-year average, it is 51% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +81.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Short interest is a burden
20.9% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #32 of 594 in the industry
Based on market cap of $9B.
SYRE#30 Spyre Therapeutics Inc $9B PER - 
PTGX#31 Protagonist Therapeutics Inc $9B PER 136.1 TGTX#32 TG Therapeutics Inc $9B PER 20.6 
CYTK#33 Cytokinetics Inc $9B PER - 
ARWR#34 Arrowhead Pharmaceuticals Inc $8B PER - 
FAQ
What kind of company is TGTX?
TGTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TGTX?
The market cap of TGTX is approximately $8.6B, ranking 1,004 within its sector.
What is the P/E ratio of TGTX?
TGTX has a P/E ratio of approximately 20.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for TGTX?
TGTX has recorded a 52-week high of $59.30 and a low of $26.76.
